News Snapshot:
The threat of delisting amid heightened tension between the two economic giants is hampering the overseas expansion plans of Chinese biotech firms, says Scott Moore of the University of Pennsylvania. Biotech industry in China and the US ‘will be shaped’ by bilateral tensions, says scholar at University of Pennsylvania.Photo: Shutterstock US-listed Chinese stocks Delisting risk, souring relations are hurdles for Chinese biotech firms seeking to enter US market, analyst says Biotech industry in China and the US ‘will be shaped’ by bilateral tensions, says scholar at University of Pennsylvania Several Chinese biotech and pharmaceutical firms were added to a list...
